000			03598nam a22003855i 4500
001			86580
003			ES-MaUEC
005			20230207040605.0
007			cr nn 008mamaa
008			151105s2016 ja | s |||| 0|eng d
020			_a9784431557142
040			_aES-MaUEC
050		4	_aRC643 _b2016 EB
082	0	4	_a616.15
245	1	0	_aMolecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia _cedited by Masahiro Kizaki
250			_a1st ed.
260			_aTokyo _bSpringer Japan _c2016
300			_a1 recurso en línea (VIII, 193 páginas) _b26 ilustraciones, 20 ilustraciones en color
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_a1. Identification and Biology of CML Stem Cells.-�2. Molecular Mechanisms of CML Stem Cell Maintenance -- 3. Roles for Signaling Molecules in the Growth and Survival of CML Cells.-�4. Goal of CML Treatment in the Tyrosine Kinase Inhibitor Era.-�5. Biomarkers for Determining the Prognosis of CML -- 6. Updated European Leukemia Net Recommendations for the Management of CML -- 7. Optimal Monitoring of CML Treatment: Molecular and Mutation Analysis -- 8. Recommendations for Management of CML in the Era of Second-Generation TKIs -- 9. Role of New TKIs and Combinations with Interferon-Ü for the Treatment of CML -- 10. Safety Profiles of First-Line TKIs and Managing Adverse�Effects -- 11. Molecular Mechanism of TKI Resistance and Potential Approaches to Overcome Resistance -- 12. Discontinuation of Therapy and Treatment-Free Remission in CML.
520	3		_aMolecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia provides a comprehensive understanding of the recent molecular genetics of Chronic Myelogenous Leukemia (CML) and a characterization of the molecular targets for drug development. Included are therapeutic implications, diagnosis, and prognosis for understanding and facilitating daily practice in the management of patients with CML. Understanding of the pathogenesis and therapy of hematological malignancies such as CML has grown significantly in recent years. This development owe much to the progress in molecular biology and now makes a major contribution to diagnosis and to treatment that pharmacologically targets the molecular events of CML. Molecular targeting therapy with newly developed agents such as small molecules and antibodies for hematological malignancies are being discovered after years of research. Some of these, including tyrosine kinase inhibitors such as imatinib, nilotinib, and dasatinib, lead to increased survival rates and improved therapies. With the opinion leaders of basic and clinical research in the field as authors, this book reviews recent advances in the biology of CML.
710	2		_aSpringerLink (Online service) _0Local _9106996
942			_2lcc _cLE
650		7	_aMedicina _0comprobar BNE19900959047 _2embne _9405021
650		7	_9140122 _aHematología _0comprobar BNE19900981064 _2embne
700	1		_aKizaki, Masahiro _eeditor literario _0Local _9100406
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-4-431-55714-2 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9784431557142
907			_a.b1295858x _b10-10-17 _c21-11-16
988			_aSpringer_Medicine_2016
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _gja _h0
945			_aRC643 .M654 2016 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11600147 _z06-04-17
999			_c86580 _d86580 _x1